- Home
- CVAC vs OCS Comparison
CVAC vs OCS Comparison
Compare CVAC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- OCS
- Stock Information
- Founded
- CVAC 2000
- OCS 2003
- Country
- CVAC Germany
- OCS Switzerland
- Employees
- CVAC N/A
- OCS N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- OCS Health Care
- Exchange
- CVAC Nasdaq
- OCS Nasdaq
- Market Cap
- CVAC 818.8M
- OCS 916.3M
- IPO Year
- CVAC 2020
- OCS N/A
- Fundamental
- Price
- CVAC $3.30
- OCS $21.41
- Analyst Decision
- CVAC Hold
- OCS Strong Buy
- Analyst Count
- CVAC 3
- OCS 5
- Target Price
- CVAC $10.00
- OCS $28.80
- AVG Volume (30 Days)
- CVAC 617.5K
- OCS 63.6K
- Earning Date
- CVAC 11-12-2024
- OCS 03-17-2025
- Dividend Yield
- CVAC N/A
- OCS N/A
- EPS Growth
- CVAC N/A
- OCS N/A
- EPS
- CVAC N/A
- OCS N/A
- Revenue
- CVAC $70,565,734.00
- OCS $1,027,571.00
- Revenue This Year
- CVAC $742.57
- OCS $7.98
- Revenue Next Year
- CVAC N/A
- OCS $853.39
- P/E Ratio
- CVAC N/A
- OCS N/A
- Revenue Growth
- CVAC 75.11
- OCS N/A
- 52 Week Low
- CVAC $2.22
- OCS $10.55
- 52 Week High
- CVAC $5.28
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CVAC 39.12
- OCS 52.07
- Support Level
- CVAC $3.53
- OCS $20.95
- Resistance Level
- CVAC $3.72
- OCS $21.86
- Average True Range (ATR)
- CVAC 0.18
- OCS 0.56
- MACD
- CVAC -0.06
- OCS -0.26
- Stochastic Oscillator
- CVAC 10.96
- OCS 56.18
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.